高级检索
当前位置: 首页 > 详情页

Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China [2]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China [3]Yunnan Blood Disease Clinical Medical Center, The First People’s Hospital of Yunnan Province, Kunming, China [4]Yunnan Blood Disease Hospital, The First People’s Hospital of Yunnan Province, Kunming, China [5]Department of Cardiology, 920th Hospital of Joint Logistics Support Force, Kunming, China
出处:
ISSN:

关键词: acute promyelocytic leukemia (APL) early death (ED) coagulopathy intracranial hemorrhage (ICH) interleukin-17A (IL-17A)

摘要:
IntroductionAcute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) with a better prognosis. But early death (ED) rate remains high. APL patients are simultaneously accompanied by coagulopathy and hyperinflammation at the onset. It is not known what effects cytokines have on ED and coagulopathy in these patients. Therefore, the purposes of this study are to explore the clinical differences between APL and other types of AML, the link between cytokines and coagulopathy in newly diagnosed APL, and their roles in the ED for APL. MethodsThis study retrospectively collected the information of 496 adult patients with AML (age >= 14 years at admission) newly diagnosed in the First People's Hospital of Yunnan Province between January 2017 to February 2022, including 115 APL patients. The difference of clinical manifestations between two groups [APL and AML (non-APL)] was statistically analyzed. Then, the factors affecting ED in APL patients were screened, and the possible pathways of their influence on ED were further analyzed. ResultsThe results indicate APL at the onset have a younger age and higher incidence of ED and DIC than other types of AML. Intracranial hemorrhage (ICH), age, and PLT count are found to be independent factors for ED in newly APL, among which ICH is the main cause of ED, accounting for 61.54% (8/13). The levels of cytokines in newly APL are generally higher than that in AML (non-APL), and those in the group of ED for APL were widely more than the control group. IL-17A and TNF-beta are directly related to the ED in newly APL, especially IL-17A, which also affects ICH in these patients. Moreover, the increase of IL-17A and TNF-beta cause the prolongation of PT in APL patients, which reflected the exogenous coagulation pathway. However, they have no effect on APTT prolongation and FIB reduction. Thus, it is speculated that IL-17A leads to early cerebral hemorrhage death in newly APL by inducing tissue factor (TF) overexpression to initiate exogenous coagulation and further leading to excessive depletion of clotting factors and prolongation of PT. ConclusionsIn conclusion, compared with other types of AML, APL patients have a younger age of onset and high inflammatory state, and are more likely to develop into DIC and die early. Age, and PLT count at diagnosis are independent factors for ED of APL, especially ICH. IL-17A is confirmed to be an independent risk factor for ED and ICH of newly APL. Hence, IL-17A may serve as a predictor of ED in newly diagnosed APL patients, and controlling its expression probably reduce ED in these patients.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2022]版:
Q1 IMMUNOLOGY
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China [2]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China [3]Yunnan Blood Disease Clinical Medical Center, The First People’s Hospital of Yunnan Province, Kunming, China [4]Yunnan Blood Disease Hospital, The First People’s Hospital of Yunnan Province, Kunming, China
通讯作者:
通讯机构: [1]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China [2]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China [3]Yunnan Blood Disease Clinical Medical Center, The First People’s Hospital of Yunnan Province, Kunming, China [4]Yunnan Blood Disease Hospital, The First People’s Hospital of Yunnan Province, Kunming, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82490 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号